[ET Net News Agency, 14 July 2020] Sino Biopharmaceutical Limited (01177) said
"Iopamidol Injection" (brand name: Qinglida), a X-ray contrast agent developed by the
group, has obtained approval for drug registration granted by the National Medical
Products Administration of the People's Republic of China and is deemed to have passed the
Consistency of Quality and Efficacy Evaluation for Generic Drugs.
The approval for launch of this product will form a differentiated product portfolio
with the existing Iodixanol Injection (brand name: Qingliming) of the group to enhance the
group's strength in the field of contrast agents.
Iopamidol injection is an X-ray non-ionic iodine contrast agent, which can enhance the
development of pictures of human tissues or organs and provide a reliable clinical
diagnosis basis for X-ray examination of patients. (RC)